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Tuberculosis (TB) is a leading cause of death among people living with 
HIV, accounting for almost 500 000 HIV/AIDS deaths worldwide 
in 2007.1 In South Africa, almost 1% of the general population 
is estimated to develop TB each year, of whom 73% are HIV-
coinfected. Almost 100 000 South Africans were estimated to have 
died of HIV-associated TB in 2007.1 A sustained commitment to 
scale up interventions to treat and prevent HIV-associated TB cases 
is urgently needed.2
Optimum management of HIV-associated TB patients requires a 
combination of effective TB treatment, co-trimoxazole preventive 
therapy and antiretroviral therapy (ART).3 HIV testing for TB 
patients is a critical entry point for this package of interventions; yet 
in 2007 only 16% of notified TB patients worldwide knew their HIV 
status.1 Rates of HIV testing may be increased by a shift from the 
traditional model of voluntary counselling and testing (in which the 
decision to test is left with the patient) to provider-initiated testing 
and counselling (PITC).4,5 In the provider-initiated model, HIV 
testing is included as a routine part of the diagnostic process unless 
the patient specifically opts out. Implementation of PITC has resulted 
in rapid improvements in rates of HIV testing and provision of 
appropriate care for TB patients in Kenya, for example.6,7 Overall rates 
of HIV testing in TB patients in Africa are also improving, reaching 
37% of notified cases in 2007.1
We have previously documented the extraordinarily high rates of 
HIV-associated TB in impoverished townships in Cape Town.8,9 In 
one of these communities, PITC was scaled up by the TB control 
programme in 2005, and rates of HIV testing among TB patients 
increased from very low levels to reach approximately 90% by 2008. 
In the present study, we explored whether the increase in rates of 
HIV testing in TB clinics in this community was associated with 
improved access of patients with HIV-associated TB to a large ART 
clinic serving this community.
Methods
Antiretroviral treatment service
The study was in Gugulethu township, Cape Town, where the 
antenatal HIV prevalence is approximately 30% and the annual TB 
notification rate exceeds 1 500/100 000 population.10,11 The Hannan 
Crusaid ART clinic opened in 2002, providing community-based 
access to treatment for almost 4 000 patients by the end of 2008. All 
enrolled patients gave written informed consent for data collection, 
as approved by the Research Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town. The national 
ART programme provided treatment for those with World Health 
Organization (WHO) stage 4 disease or a blood CD4 cell count 
<200 cells/μl. The extraordinarily high burden of previous or active 
TB among patients accessing this ART service has been previously 
characterised.10,12-14
Patients were enrolled in this ART service following referral from 
several different primary care clinics in this community, including 
HIV care clinics, antenatal clinics and TB clinics. ART clinics and Corresponding author: S Lawn (stevelawn@yahoo.co.uk)
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Background. Timely initiation of antiretroviral treatment (ART) is 
a critical component of the case management of patients with HIV-
associated tuberculosis (TB) and advanced immunodeficiency. We 
sought to determine the impact of the introduction of provider-
initiated HIV-testing in TB clinics in 2005 on subsequent referrals 
of patients with HIV-associated TB at a community-based ART 
service in Cape Town.
Methods. Retrospective analysis of an ART cohort database (2002 - 
2008) stratified by calendar periods.
Results. Between 2002 and 2008, 3 770 ART-naive adults enrolled 
in the ART service. Overall, 27.4% of these patients had been 
referred from TB clinics with a diagnosis of HIV-associated TB. 
This proportion increased from 16.0% of referrals in the period 
2002 - 2005 prior to the introduction of provider-initiated HIV 
testing, to 34.7% in 2007 - 2008 (p<0.001). The median duration of 
TB treatment completed prior to referral decreased from 3 months 
to 1 month (p<0.001) and patients enrolled with higher median 
CD4 cell counts (71 cells/µl v. 95 cells/µl; p<0.001). Moreover, the 
proportion with recurrent TB episodes decreased from 8.6% to 
3.2% (p<0.001).
Conclusions. Introduction of provider-initiated HIV testing by 
the TB control programme was temporally associated with a major 
increase in referrals of patients with HIV-associated TB to this 
ART service, a progressive decline in referral delay, improvements 
in baseline CD4 cell counts, and fewer recurrent TB episodes. Such 
trends are likely to be associated with improved survival, and these 
data strongly support this HIV-testing strategy.
S Afr Med J 2011;101:258-262. 
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TB clinics were based in separate facilities and under the control 
of different administrative structures within the health services. TB 
diagnoses within TB clinics were made according to South African 
national TB control programme guidelines.15 In 2005, provider-
initiated HIV testing and counselling for TB patients using point-of-
care diagnostics was scaled up within the Western Cape. Testing rates 
exceeding 90% were achieved in this district by 2008.
Data sources and case definitions
A prospectively maintained database of all patients enrolling in this 
clinic has been maintained since 2002. It includes patient baseline 
characteristics and CD4 cell counts, which were combined with 
data concerning previous and current episodes of TB. Terms used 
were: ‘Referred TB’ to refer to patients referred to the ART service 
from a TB clinic during a current course of TB treatment; ‘History 
of previous TB’ described recorded episodes of TB treatment during 
the 3 years preceding enrolment at the ART clinic which had already 
been completed or discontinued; and ‘TB on screening’ referred to 
episodes of TB diagnosed during routine screening after enrolment 
at the ART clinic but before initiation of ART.
Analysis
This was a retrospective study of patients enrolling between September 
2002 and June 2008. Analysis was restricted to ART-naive patients 
aged ≥18 years at enrolment. Enrolment dates were categorised 
into 4 periods: Period 1 from September 2002 - June 2005 covered 
the period prior to availability of provider-initiated HIV testing in 
TB clinics. Periods 2 - 4 (July 2005 - June 2006, July 2006 - June 
2007, and July 2007 - June 2008, respectively) were sequential years 
during which high rates of HIV testing were achieved in TB clinics. 
Changes in the burden of previous and current TB were determined 
among patients enrolling for ART in these 4 periods, and associations 
with the variable ‘referred TB’ were determined in univariate and 
multivariate analyses.
Differences in baseline patient characteristics between calendar 
periods were analysed by the Pearson chi-square test on categorised 
data. Proportions and 95% confidence intervals (95% CIs) were 
calculated to describe the proportions of patients with previous and 
current TB episodes in different calendar periods, and changes were 
analysed using the Pearson chi-square test. Medians were compared 
using the Wilcoxon rank sum test. To analyse variables associated 
with ‘referred TB’, odds ratios were calculated, and adjusted odds 
were calculated using logistic regression. All statistical tests were 
two-sided at α of 0.05.
Results
Baseline patient characteristics
Between September 2002 and June 2008, 3 770 ART-naive patients 
aged ≥18 years were enrolled in the ART service. Their median age 
was 33 years, 34% were male, and the median CD4 cell count was 106 
cells/µl (IQR 51 - 168). Table I shows how the baseline characteristics 
of the cohort changed according to the period of enrolment. Of note 
is that the male proportions increased substantially after 2005, and 
the median baseline CD4 cell counts progressively increased over 
time (p<0.001) (Table I).
TB among patients enrolling for 
antiretrovirals
For each calendar period, the proportion of patients who enrolled 
in the ART service while receiving a course of treatment for TB 
(‘referred TB’) was calculated. This proportion increased from 16.0% 
(95% CI 13.9 - 18.1) in the period prior to provider-initiated HIV 
testing in TB clinics (2002 - 2005) to 34.7% (95% CI 31.4 - 38.1) in 
2007 - 2008, 3 years after rapid scaling up of HIV testing (Fig. 1a) 
(p<0.001).
We also determined for each calendar period the proportions 
of patients enrolling for ART who had a history of completed 
TB treatment during the preceding 3-year period (Fig. 1b). This 
proportion decreased substantially between the periods 2002 - 2005 
and 2007 - 2008 (39.4% v. 12.5%, respectively (p<0.001). Thus, 
over calendar time, a reciprocal relationship was observed between 
increases in the proportion of patients with referred TB and decreases 
in the proportions with a history of previous TB. In contrast, the 
proportion of patients diagnosed as having active TB in the screening 
period before initiation of ART (‘TB on screening’) was relatively 
constant, ranging between 6.4% and 9.1%, with no significant trend 
over time (p>0.1) (Fig. 1c).
Factors associated with increasing referral of 
TB patients for antiretrovirals
We next explored the association between the major increases in 
referrals of patients with HIV-associated TB to the ART clinic, with 
Table I. Baseline characteristics of patients enrolling in the ARV treatment cohort over time
Patient characteristics
Period 1 (Sept 2002 - 
June 2005)
Period 2 (July 2005 - 
June 2006)
Period 3 (July 2006 - 
June 2007)
Period 4 (July 2007 - 
June 2008) p-value
Number enrolled 1143 945 899 783 -
Age, median (IQR) 32 (28 -38) 32 (28 - 39) 33 (28 - 39) 34 (29 - 40) > 0.1
Male (proportion) 316 (28) 331 (35) 347 (39) 283 (36) <0.001
CD4 counts *
median (IQR) 98 (48 - 154) 105 (47 - 167) 107 (55 - 168) 120 (56 - 186)
0 - 50 (%) 256 (26) 213 (27) 180 (24) 157 (22)
<0.001
51 - 100 (%) 244 (25) 172 (22) 172 (23) 144 (20)
101 - 150 (%) 216 (22) 166 (21) 172 (23) 133 (19)
151 - 200 (%) 156 (16) 120 (15) 126 (17) 141 (20)
>200 (%) 101 (10) 123 (15) 113 (15) 133 (19)
*Data available for 3 238 patients.
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the changes in baseline characteristics of the cohort and with calendar 
period (Table II). In adjusted analyses, the proportion of patients 
referred with TB was strongly associated with male sex and lower 
CD4 cell counts. However, following scale-up of provider-initiated 
HIV testing in 2005, the odds of patients being referred to the ART 
programme with a diagnosis of TB increased by 240 - 300 per cent 
compared with the period prior to this (p<0.001) (Table II).
Changes in the timing of referral of TB 
patients
For patients referred to the ART clinic with TB, we next determined 
the duration of TB treatment completed prior to enrolment (Fig. 2). 
This decreased from a median of 3 months in the first calendar period 
(2002 - 2005) to 1 month in the last calendar period (2007 - 2008) 
(p<0.001). Moreover, the baseline CD4 cell counts of these patients 
at enrolment also significantly increased from 71 cells/µl (IQR 26 - 
122) in the first calendar period, to 95 cells/µl (IQR 41 - 159) in the 
last calendar period (p<0.01). Therefore, following introduction of 
provider-initiated HIV testing in 2005, patients referred to the ART 
programme arrived earlier in the course of their TB treatment and 
with less advanced immunodeficiency.
Changing frequency of recurrent TB
We next determined the proportions of patients with recurrent TB, 
representing those with >1 episode of TB in the preceding 3 years, 
including episodes of previous TB, referred TB and TB diagnosed on 
screening. The proportion in 2002 - 2005 was 8.6% (95% CI 7.0 - 10.2), 
was similar in 2005 - 2006, but thereafter decreased to 3.2% (95% CI 
2.2 - 4.7) in 2007 - 2008 with unadjusted odds of 0.33 (Fig. 3).
Discussion
Our study documented the burden of previous and current TB 
episodes among patients enrolling in a large ART clinic in a South 
African township. We found that the scaling up of provider-initiated 
HIV testing in TB clinics in the district was temporally associated 
with large increases in the proportion of patients referred to this 
ART service who had a diagnosis of TB. This increase in referrals 
was accompanied by marked reductions over time in the duration of 
TB treatment completed prior to enrolment in the ART service and 
a gradual improvement in baseline CD4 cell counts. The proportions 
of patients with recurrent TB episodes also decreased substantially. 
These data suggest that marked improvements have occurred in the 
efficiency of HIV diagnosis and referral for ART of patients with 
HIV-associated TB in the district.
The study was in a community where TB care and HIV care are 
not integrated but are provided in separate health facilities, which 
represents a potential obstacle to providing quality care for co-infected 
Fig. 2. Duration of TB treatment received by patients prior to enrolling in the 
ART programme decreased substantially between 2002 and 2008 (p<0.001). 
Box and whisker plots show the median (bar), the 25th and 75th centiles 
(box) and the 10th and 90th centiles (whiskers). The dashed line indicates 
when provider-initiated HIV testing and counselling was implemented in 
local TB clinics.
Fig. 1. The proportions (as %) of patients entering the antiretroviral treat-
ment (ART) cohort who: (1a) had been referred to the ART programme dur-
ing TB treatment (‘referred TB’); (1b) had a history of previous treatment 
for TB within the 3 years prior to enrolment; (1c) had active TB diagnosed 
during the screening period at entry to the ART programme. Data are shown 
for patients enrolled during 4 sequential analysis periods. The dashed line 
indicates when provider-initiated HIV testing and counselling was imple-
mented in local TB clinics.
Fig 1a
Fig 1b
Fig 1c
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patients. Nevertheless, the data show that substantial improvements 
in the referral process have occurred over time and are consistent 
with increases in the proportion of patients reported to have TB at 
baseline in ART services in Khayelitsha township.16 As the proportion 
of patients referred during TB treatment increased, the proportion of 
patients with a history of completed TB treatment was reciprocally 
reduced. This trend is consistent with an increasing proportion of TB 
patients being HIV-tested and referred for ART during the course of 
TB treatment rather than after completing treatment.
The temporal trends in TB referrals could have arisen because 
of changes in the risk profile of the cohort or changes in TB 
burden in the community. However, the proportion of patients with 
TB newly diagnosed on entry to the ART programme remained 
relatively constant over time (Fig. 1c) and, in analyses adjusted for 
baseline patient characteristics, the temporal association between 
the proportions of patients referred with TB and calendar period 
remained very strong (Table II). Being referred with TB was also 
strongly associated with being male, which is likely to reflect in 
part the biologically greater risk of men developing TB. However, 
an additional contributing factor is that approximately 10% of 
women enrolling in this cohort were referred from antenatal clinics, 
representing a competing route of referral.
We suspect that the lower median CD4 cell counts among patients 
referred with TB before 2005 was associated with use of voluntary 
counselling and HIV testing, uptake of which was low and likely to 
have been biased towards selecting those with the most advanced 
manifestations of HIV. Subsequent provision of provider-initiated 
testing and counselling with high uptake was much less likely to be 
biased in this way, potentially contributing to the observed rises in 
median CD4 cell counts over time. More rapid referral of patients 
for ART might also have contributed to this rising trend in CD4 cell 
counts.
Patients with HIV-associated TB entering ART services have 
very high mortality risk10 and TB is the most common cause of 
death during the initial months of ART in sub-Saharan Africa.10,11,17 
The 2010 revision of the WHO international guidelines for ART 
resource-limited settings therefore recommend that patients with 
HIV-associated TB should commence ART as soon as possible after 
initiation of TB treatment.18 Early referral of TB patients for ART is 
therefore a critical component of optimal care. It was consequently 
encouraging that the median referral delay decreased over time from 
3 months to 1 month. However, even a 1-month referral delay is 
undesirable19 and integrated systems of care are required to reduce 
this further.
Use of ART is associated with a 67% reduction in TB incidence 
rates20 and a halving of TB recurrence rates.21 Therefore, with 
increasing access of patients with HIV-associated TB to ART in this 
community, a marked reduction in the proportion of patients with 
recurrent TB episodes is not surprising (Fig. 3). The delay in the 
reduction of this proportion until 2006 - 2007 is probably attributable 
to the large residual pool of HIV-infected patients in the community 
who had already completed a course of TB treatment. The proportion 
with recurrent disease together with the other parameters measured 
in this study might be used as indicators to assess the quality of care 
for patients with HIV-associated TB.
Strengths of this study include the very well-characterised ART 
cohort in a very high TB burden setting. The striking temporal 
trends in TB referrals were carefully analysed to control for potential 
confounders, although the role of other factors affecting referral and 
enrolment patterns cannot be excluded. Weaknesses include that 
Fig. 3. Proportions of patients entering the ART cohort who had recurrent 
TB, defined as a patient with a past history of TB in the preceding 3 years 
plus a second episode being treated on enrolment to the cohort. Data are 
shown for patients enrolled during 4 sequential analysis periods. The dashed 
line indicates when provider-initiated HIV testing and counselling was im-
plemented in local TB clinics.
Table II. Factors associated with patients being referred to the ARV treatment clinic with tuberculosis
Unadjusted odds 
ratio p-value Adjusted odds ratio p-value
Age <30 1 1
>30 1.18 (1.01 - 1.38) 0.027 1.01 (0.85 - 1.20) 0.90
Sex Female 1 1
Male 1.90 (1.64 - 2.21) <0.001 1.82 (1.54 - 2.16) <0.001
CD4 cell count 0 - 50 1 1
51 - 100 0.75 (0.61 - 0.93) <0.01 0.76 (0.61 - 0.95) 0.016
101 - 150 0.50 (0.40 - 0.63) <0.001 0.50 (0.40 - 0.64) <0.001
151 - 200 0.41 (0.32 - 0.53) <0.001 0.40 (0.31 - 0.52) <0.001
>200 0.52 (0.40 - 0.67) <0.001 0.49 (0.38 - 0.64) <0.001
Calendar period 2002 - 2005 1 1
2005 - 2006 2.39 (1.94 - 2.95) <0.001 2.42 (1.92 - 3.05) <0.001
2006 - 2007 2.37 (1.92 - 2.93) <0.001 2.49 (1.97 - 3.15) <0.001
2007 - 2008 3.00 (2.25 - 3.47) <0.001 3.00 (2.36 - 3.81) <0.001
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these data relate to a single ART service, and losses during the referral 
process from TB clinics to the ART clinic were not studied. Further 
operational research that tracks patients between the two services 
is needed. Moreover, the likely survival benefits resulting from 
increased HIV testing and referral for ART were not measured.
Conclusion
The data suggest that the implementation of provider-initiated HIV 
testing in TB clinics in this community was temporally associated 
with substantial increases in referral of patients for ART and 
improvements in the timeliness of referral. Such trends are likely to 
be associated with improved treatment outcomes. These findings 
support the new South African national policy of much wider 
implementation of provider-initiated HIV testing and counselling.22
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